Induced pluripotent stem cells (iPSCs) can differentiate into mineralizing cells and thus have a great potential in application in engineered bone substitutes with bioactive scaffolds in regeneration medicine. In the current study we characterized and demonstrated the pluripotency and osteogenic differentiation of mouse iPSCs. To enhance the osteogenic differentiation of iPSCs, we then transduced the iPSCs with the potent transcription factor, nuclear matrix protein SATB2. We observed that in SATB2-overexpressing iPSCs there were increased mineral nodule formation and elevated mRNA levels of key osteogenic genes, osterix (OSX), Runx2, bone sialoprotein (BSP) and osteocalcin (OCN). Moreover, the mRNA levels of HoxA2 was reduced after SATB2 overexpression in iPSCs. The SATB2-overexpressing iPSCs were then combined with silk scaffolds and transplanted into critical-size calvarial bone defects created in nude mice. Five weeks post-surgery, radiological and micro-CT analysis revealed enhanced new bone formation in calvarial defects in SATB2 group. Histological analysis also showed increased new bone formation and mineralization in the SATB2 group. In conclusion, the results demonstrate that SATB2 facilitates the differentiation of iPSCs towards osteoblast-lineage cells by repressing HoxA2 and augmenting the functions of the osteoblast determinants Runx2, BSP and OCN.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100415 | PMC |
http://dx.doi.org/10.1016/j.biomaterials.2011.03.053 | DOI Listing |
PLoS One
January 2025
Ionis Pharmaceuticals, Inc., Carlsbad, CA, United States of America.
Lateral Meningocele Syndrome (LMS), a disorder associated with NOTCH3 pathogenic variants, presents with neurological, craniofacial and skeletal abnormalities. Mouse models of the disease exhibit osteopenia that is ameliorated by the administration of Notch3 antisense oligonucleotides (ASO) targeting either Notch3 or the Notch3 mutation. To determine the consequences of LMS pathogenic variants in human cells and whether they can be targeted by ASOs, induced pluripotent NCRM1 and NCRM5 stem (iPS) cells harboring a NOTCH36692-93insC insertion were created.
View Article and Find Full Text PDFBackground: Tauopathies are a group of neurodegenerative disorders which are characterized by the accumulation of abnormal tau protein in the brain. However, the mechanistic understanding of pathogenic tau formation and spread within the brain remains elusive. Astrocytes are major immune reactive cells in the brain and have been implicated in exacerbating tau pathology by releasing extracellular vesicles (AEVs) containing pro-inflammatory cytokines and chemokines upon activation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
UK Dementia Research Institute at Cardiff University, Cardiff, South Glamorgan, United Kingdom.
Background: Genome-wide association studies (GWAS) in Alzheimer's disease (AD) implicate complement in pathogenesis. Complement receptor 1 (CR1; CD35) is a top AD-associated GWAS hit; the long variant, CR1*2, associates with risk. The roles of CR1 in brain and how variants influence AD risk are poorly understood.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neural Stem Cell Institute, Rensselaer, NY, USA.
Background: Up to 84% of patients with Alzheimer's Disease (AD) have vascular damage which precedes cognitive decline. Inflammation induces changes in blood-brain-barrier (BBB) integrity, though the link between induction of inflammation and AD is unclear. IL1β, a cytokine upregulated in patients with AD and in mouse models of the disease, is released and interacts with IL1R1 and its obligate co-receptor, IL1RAP, to induce downstream signaling.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indianapolis, IN, USA.
Background: The National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) is continuing to develop a bank of induced pluripotent stem cells (iPSCs) that are available by request to the Alzheimer's disease (AD) research community.
Methods: As part of the pipeline for quality control of received cell lines, DNA was extracted for all lines and was submitted for whole genome sequencing (WGS). Paired-end WGS data was generated using the Illumina NovaSeq 6000 and processed following GATK best practices using the Sentieon pipeline.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!